Few urology residents receive didactic education on gender-affirming care, survey shows.
The programs present an opportunity for urologists to evaluate how they practice.
Adding abiraterone acetate (ZYTIGA) to androgen deprivation therapy for the management of patients with metastatic castration-naïve prostate cancer does not increase medical resource utilization.
The treatment method may delay need for systemic therapy in men with oligometastatic prostate cancer.
“As many other practices have found, [advanced practice providers] help us to improve access, increase capacity, keep our costs low, and just as important, they allow our urologists to focus on more complex functions,” writes Barry A. Kogan, MD.
The plaintiff claimed that the urologist should have performed TURP.
Study findings bolster the idea that frequent repeat biopsies are unnecessary.
Learn about this and other products in the pipeline for prostate cancer and bladder cancer.